Although patients with non-ST-elevation acute coronary syndromes (NSTE-ACS) have been shown to benefit with an early invasive therapy as compared with medical management, especially in high-risk ...

There are different explanations regarding the conflicting evidence for perioperative β-blocker use ... reflects the high prevalence of underlying coronary artery disease. Preoperative coronary ...

In MI patients with preserved heart function, beta-blockers are linked to higher depressive symptoms, indicating a need for ...

Acute coronary syndrome (ACS) is a medical term that categorizes three conditions that cause a sudden, life-threatening ...

Causes include a build-up of plaque and plaque rupture in coronary arteries ... Sometimes coronary artery disease can cause an acute coronary syndrome in the absence of plaque rupture and ...

Visit us on Facebook. Opens in a new tab or window Visit us on X. Opens in a new tab or window Visit us on Instagram. Opens in a new tab or window Visit us on LinkedIn. Opens in a new tab or ...

This study assessed the effectiveness of various risk stratification tools, including clinical decision rules and troponin tests, in helping general practitioners rule out acute coronary syndrome ...

The risk for developing frailty was slightly lower for people who took beta blockers, a new study finds ... high cholesterol and 24.6% had prior acute coronary syndrome. All of the data came ...

Severe obstructive coronary artery disease. Avoid administration within 1–2 weeks post MI or in acute coronary syndrome ... and CHF possible with beta-blockers. Avoid concomitant phenytoin ...

Immediately reinstate Toprol-XL if angina worsens or acute coronary ischemia develops ... In general, do not give beta-blockers to patients with bronchospastic disease. Toprol-XL may be used ...

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

Nair A, Bolaji O, Zonshayn D, Desai D, Cheriyath P, Okere A. Racial, ethnic, and gender disparities among patients with acute coronary syndrome in the setting of COVID-19: a nationwide analysis.